- Home
- QFIN vs JAZZ Comparison
QFIN vs JAZZ Comparison
Compare QFIN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- JAZZ
- Stock Information
- Founded
- QFIN 2016
- JAZZ 2003
- Country
- QFIN China
- JAZZ Ireland
- Employees
- QFIN N/A
- JAZZ N/A
- Industry
- QFIN Finance: Consumer Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- JAZZ Health Care
- Exchange
- QFIN Nasdaq
- JAZZ Nasdaq
- Market Cap
- QFIN 5.9B
- JAZZ 6.5B
- IPO Year
- QFIN 2018
- JAZZ 2007
- Fundamental
- Price
- QFIN $38.49
- JAZZ $125.04
- Analyst Decision
- QFIN Strong Buy
- JAZZ Buy
- Analyst Count
- QFIN 1
- JAZZ 14
- Target Price
- QFIN $37.50
- JAZZ $173.93
- AVG Volume (30 Days)
- QFIN 1.6M
- JAZZ 539.6K
- Earning Date
- QFIN 11-19-2024
- JAZZ 11-06-2024
- Dividend Yield
- QFIN 2.97%
- JAZZ N/A
- EPS Growth
- QFIN 42.14
- JAZZ 458.10
- EPS
- QFIN 4.99
- JAZZ 7.04
- Revenue
- QFIN $2,449,056,522.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- QFIN $6.22
- JAZZ $7.51
- Revenue Next Year
- QFIN $4.03
- JAZZ $6.82
- P/E Ratio
- QFIN $7.68
- JAZZ $17.38
- Revenue Growth
- QFIN 9.41
- JAZZ 5.23
- 52 Week Low
- QFIN $13.71
- JAZZ $99.06
- 52 Week High
- QFIN $40.31
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- QFIN 65.01
- JAZZ 56.71
- Support Level
- QFIN $37.55
- JAZZ $121.73
- Resistance Level
- QFIN $40.31
- JAZZ $126.23
- Average True Range (ATR)
- QFIN 1.34
- JAZZ 2.79
- MACD
- QFIN 0.16
- JAZZ -0.16
- Stochastic Oscillator
- QFIN 89.69
- JAZZ 68.98
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.